The Role of the Radiotherapy in Endometrial Cancer


Abstract views: 108 / PDF downloads: 54

Authors

DOI:

https://doi.org/10.5281/zenodo.8237661

Keywords:

Endometrial cancer, prognosis, radiotherapy

Abstract

Endometrial cancer is the most common gynecological cancer in western countries and endometrial cancer incidence has been increased in the last few decades with increased mortality rates. Surgery has main role in the treatment of patients with endometrial cancer and adjuvant management is required in certain clinicopathological risk factors. In this study, the effect of adjuvant radiation therapy (RT) on overall survival (OS) and disease-free survival (DFS) according to risk groups in patients with endometrial cancer was evaluated retrospectively. A total of 512 patients who were diagnosed with endometrial cancer were included in the study. Based on the prognostic factors, risk groups were recorded as low, intermediate, high-intermediate, high risk, and advanced/metastatic. Patients’ OS and DFS were calculated using Kaplan– Meier method. Median age was 58 years (range, 28–82). The number of patients who had low risk group, low-intermediate risk, high-intermediate risk, high-risk and advanced risk were 139 (28%), 84 (16.9%), 50 (10.1%), 182 (36.6%) and 42 (8.5%), respectively. Median OS and DFS were 14.1 years (range, 0.1-20.7) and 1.3 years (range, 0.7-11.2), respectively. OS and DFS were found to be better in patients who received RT alone in all risk groups except the advanced/metastatic risk group (p<0.001). Currently, adjuvant therapy is no longer recommended for patients with low-risk endometrial cancer. Although adjuvant treatment is required in high- risk patients, in contrast to previous studies, the addition of chemotherapy to adjuvant RT, poor effect on prognosis in this study.

References

Colombo, N.; Creutzberg, C. & Amant, F. (2016), ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer, 26(1):2-30. Epub 2015/12/10. doi: 10.1097/IGC.0000000000000609.

Concin, N.; Matias-Guiu, X. & Vergote, I. (2021), ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer, 31(1):12-39. doi: 10.1136/ijgc-2020-002230. Epub 2020 Dec 18.

Creutzberg, C.L.; van Putten, W.L. & Koper, P.C. (2000), Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post-Operative Radiation Therapy in Endometrial Carcinoma, Lancet, 355(9213):1404-11. Epub 2000/05/03. doi: 10.1016/s0140-6736(00)02139-5.

de Boer, S.M.; Powell, M.E. & Mileshkin, L. (2018), PORTEC study group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol, 19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

Hogberg T. (2008). Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials. Clin Oncol (R Coll Radiol), 20:463-469.

Hogberg, T.; Signorelli, M. & de Oliveira, C.F. (2010), Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer, 46(13):2422-31. doi: 10.1016/j.ejca.2010.06.002. Epub 2010 Jul 7.

Keys, H.M.; Roberts, J.A. & Brunetto, V.L. (2004), A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol, 92(3):744-51. Epub 2004/02/27. doi: 10.1016/j.ygyno.2003.11.048.

Koh, W.J.; Tran, A.B. & Douglas, J.G. (2001), Radiation therapy in endometrial cancer. Best Pract Res Clin Obstet Gynaecol, 15:417-432.

Lybeert, M.L.; van Putten, W.L. & Brolmann, H.A. (1998), Postoperative radiotherapy for endometrial carcinoma. Stage I. Wide variation in referral patterns but no effect on long-term survival in a retrospective study in the southeast Netherlands. Eur J Cancer, 34(4):586-90. Epub 1998/08/26. doi: 10.1016/s0959-8049(97)10087-9.

Maggi, R.; Lissoni, A. & Spina, F. (2006), Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer, 95(3):266-71. doi: 10.1038/sj.bjc.6603279. Epub 2006 Jul 25.

Randall, M.E.; Filiaci, V. & McMeekin, D.S. (2019), Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. J Clin Oncol, (21):1810-1818. doi: 10.1200/JCO.18.01575. Epub 2019 Apr 17.

Raffone, A.; Travaglino, A. & Mascolo, M. (2019), TCGA molecular groups of endometrial cancer: Pooled data about prognosis. Gynecol Oncol, 155(2):374-383. doi: 10.1016/j.ygyno.2019.08.019. Epub 2019 Aug 29.

Reboux, P.A.; Azais, H. & Canova, C.H. (2019), Impact of vaginal brachytherapy in intermediate and high-intermediate risk endo¬metrial cancer: a multicenter study from the FRANCOGYN group. J Gynecol Oncol, 30:e53.

Scholten, A.N.; van Putten, W.L. & Beerman, H. (2005), Postoperative ra¬diotherapy for stage 1 endometrial carcinoma: long-term out¬come of the randomized PORTEC trial with central pathology re¬view. Int J Radiat Oncol Biol Phys, 63:834–8.

Secord, A.A.; Geller, M.A. & Broadwater, G. (2013), A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecol Oncol, 128:65-70.

Susumu, N.; Sagae, S. & Udagawa, Y. (2008), Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol, 108(1):226-33. doi: 10.1016/j.ygyno.2007.09.029. Epub 2007 Nov 9.

Downloads

Published

2023-07-25

How to Cite

Kuzhan, A. (2023). The Role of the Radiotherapy in Endometrial Cancer. Euroasia Journal of Mathematics, Engineering, Natural & Medical Sciences, 10(28), 121–129. https://doi.org/10.5281/zenodo.8237661

Issue

Section

Articles